A clinical and laboratory study of benign multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Predicting the long-term course and prognosis of MS is crucial for patient management and treatment strategies.
• Factors influencing benign versus progressive forms of MS require further investigation.

Purpose of the Study:

• To identify clinical and laboratory predictors of benign multiple sclerosis in a hospital-based cohort.
• To assess the association between early disease characteristics and long-term prognosis.
• To evaluate the utility of specific laboratory markers in predicting MS outcomes.

Main Methods:

• A hospital-based study involving 400 patients with multiple sclerosis.
• Analysis of clinical data including age of onset, remission duration, presenting symptoms, and disease progression.
• Correlation of clinical findings with laboratory tests such as CSF myelin basic protein, visual evoked response, CSF IgG, and T lymphocytes.

Main Results:

• 42% of patients with MS for over 10 years had benign disease.
• Early age of onset and long first remission were significant predictors of a good prognosis.
• Limb weakness was significantly associated with a poor outcome (p < 0.05), and a progressive disease element was less common in benign MS (p < 0.001).
• Absence of cerebrospinal fluid (CSF) myelin basic protein during remission was the only laboratory marker linked to a benign prognosis.

Conclusions:

• Early clinical features like age of onset and remission duration are key indicators for multiple sclerosis prognosis.
• Limb weakness is a significant negative prognostic factor in MS.
• Current laboratory tests, including CSF myelin basic protein, visual evoked response, CSF IgG, and T lymphocytes, have limited value in predicting long-term MS outcomes, with absence of CSF myelin basic protein being a notable exception.